- U.S. says it wants Syrian government to negotiate 'seriously' with opp
- Star Wars: The Last Jedi Spoilers: Who Are Rey's Parents?
- Zimbabwe's ruling party must fix economy to win vote: president
- Victims of Mexico military abuses shudder at new security law
- Trump to propose ending rule allowing spouses of H-1B holders to work in U.S.
- GameSpot's Best Games Of 2017 #6: Horizon: Zero Dawn
- Star Wars: The Last Jedi Review - Is It Any Good?
- Man with knife shot at Amsterdam airport; suspect is known offender
- Tillerson urges long halt to North Korea weapons tests before any talk
- Phone-based therapy sessions may help dementia caregivers cope
- Far Cry 5 Gameplay Showcases The Series' Familiar Insanity
- Peru lawmakers file motion to impeach president Kuczynski
- Brazil's Temer says pension bill 2 to 3 dozen votes short
- Free PUBG Included With Xbox One X For A Limited Time
- Fed's Quarles to recuse himself from Wells Fargo matters
- Star Wars: The Last Jedi Spoilers: Who Is Snoke?
- Supporters of Hungarian Jobbik opposition party protest over crackdown
- Sports sector wins reprieve in EU copyright reform
- Tobacco industry trumps as India court cancels stringent health labeli
- Destiny 2 Xur Location Guide: Where Is Xur And What Is He Selling? (December 15-18)
Denmark's Alk Abello suspends dividend to support North America investment
(Reuters) - Danish pharma company Alk Abello said on Monday it would invest 1 billion Danish crowns ($159 million) in its North America business, a move that is expected put a lid on earnings and revenue growth in the near term.
To support the investment, the company also plans to temporarily suspend its dividend. The news sent its shares sharply lower and they were last down 9 percent at 825 crowns, the lowest since February 2016.
The company aims to expand its allergy immunotherapy business in North America, which is world’s largest allergy market.
The pharma products maker has already an established organization in the region, where its revenue rose 17 percent year-on-year in the third quarter.
Alk Abello, which generates about one-fifth of its revenue in North America, said the expansion plan was expected to boost annual revenue growth to 10 percent or more after 2018.
With the expansion, the company expects margins to be in line with the wider specialty pharmaceutical industry in the longer run.
However, Alk Abello kept its guidance for 2017 unchanged and expects 2018 revenue to be slightly lower than in 2017.
($1 = 6.2800 Danish crowns)
Reporting by Boleslaw Lasocki; Editing by Edmund Blair and Mark Potter
Our Standards:The Thomson Reuters Trust Principles.